COMMUNIQUÉS West-GlobeNewswire

Dr. Bob Meyer D.C. Legacy in Sports Medicine Continues to Shine Bright: A Testament to Excellence
15/05/2024
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- In the fast-paced world of sports medicine, few names command as much respect and admiration as Dr. Bob Meyer, D.C. With a career spanning decades, Dr. Bob has not only [...]
Alvotech S.A. Annual General Meeting to be held June 7, 2024
15/05/2024
The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of [...]
Vaso Corporation Announces Financial Results for First Quarter 2024
15/05/2024
PLAINVIEW, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today reported its operating results for the three months ended March 31, 2024. “Total revenue for the first quarter of 2024 was [...]
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
15/05/2024
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Promex Broadens Leadership Team Expertise, Naming Matt Hansen Director of Sales and Business Development
15/05/2024
Hansen to leverage breadth of industry experience in targeting new markets SANTA CLARA, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Promex Industries , a Silicon Valley-based provider of advanced design, packaging and [...]
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
15/05/2024
ST. LOUIS, May 15, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has been invited to [...]
CloudMD Announces Go-Private Transaction with CPS Capital
15/05/2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the “ Company ” or “ CloudMD ”), an innovative health services company transforming the delivery of care, and [...]
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
15/05/2024
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to [...]
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
15/05/2024
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux Mediator TM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024. GLP [...]
Yield10 Bioscience Announces Delisting from Nasdaq
15/05/2024
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Company has received a final delisting notice [...]
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
15/05/2024
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Sienna Announces May Dividend
15/05/2024
MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) for [...]
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
15/05/2024
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
15/05/2024
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD ) , a biopharmaceutical company dedicated to advancing treatments for neurological disorders, [...]
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
15/05/2024
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a [...]
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
15/05/2024
LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, [...]
Safety Shot, Inc. (Nasdaq: SHOT) Announces Strategic C-Store Plans in Los Angeles with 7-Eleven
15/05/2024
JUPITER, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) is thrilled to announce it will be introducing Safety Shot into 50 targeted 7-Elevens in Los Angeles in June. Safety Shot is the world's [...]
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
15/05/2024
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership team with the [...]
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
15/05/2024
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo [...]

Pages